Oregon Health & Science University wins breakthrough stem-cell patent; ethics of cloning debated
By Nick Budnick,
The Oregonian
| 11. 02. 2011
Oregon Health & Science University's patent on a procedure to clone stem cells caps off a decade of work for Shoukhrat Mitalipov and his research team at OHSU's primate center.
The 2007 discovery, ranked by TIME Magazine one of the top two research advances of the year, now can be commercialized. Over the long-term, observers say, it could lead to the genetic engineering of human beings. But OHSU's announcement yesterday focused on short-term health gains.
“We believe our procedure has several advantages over other methods in developing new treatments for diseases such as Parkinson’s, multiple sclerosis, cardiac disease and spinal cord injuries,” said Mitalipov, an associate scientist in the Division of Reproductive Sciences. “For instance, because we transform a person’s own cells, there are no issues of rejection when the stem cells are transplanted back into a patient.”
What follows are links tracking the patent announcement, the earlier news and the resulting ethical debate over human cloning.
OHSU's Shoukhrat Mitalipov, Ph.D., discusses newly developed gene therapy method (OHSU via Youtube.com)
Scientists use monkey clones to extract stem cells (New York...
Related Articles
By Carl Zimmer and Marco Hernandez , The New York Times | 07.01.2026
Scientists have long dreamed of discovering the alchemy by which chemicals can be turned into life. On Wednesday, a team at the University of Minnesota announced that it had taken a major step toward that vision.
Blending together dozens of...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...
By Ed Pilkington, The Guardian | 06.12.2026
Desperate US parents paying up to $20,000 a session for a procedure scientists say could be bogus
Autistic children as young as 18 months old are being injected with human stem cells derived from umbilical cords in unapproved, unproven and...
By Tobi Thomas, The Guardian | 06.10.2026
The UK’s stem cell transplant system is potentially putting the lives of blood cancer patients at risk as a result of inadequate infrastructure and a lack of long-term planning, a parliamentary report has found.
A hematopoietic stem cell transplant, often...